Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1397 of 5804
-
Gene therapy aims to stop bladder scarring in painful bladder condition
Disease control Recruiting nowTo evaluate the efficacy and safety of Neovasculgen in interstitial cystitis with Hunner's lesions to reduce cicatricial changes in the bladder caused by electrocoagulation and to prevent secondary bladder shrinkage with a decrease in its volume.
Phase: PHASE2, PHASE3 • Sponsor: JSC NextGen • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New stroke drug shows promise in early trial
Disease control CompletedThis study is designed to determine the safety and efficacy of SHPL-49 intravenous infusion for 7 consecutive days in the treatment of acute ischemic stroke subjects.
Phase: PHASE2 • Sponsor: Shanghai Hutchison Pharmaceuticals Limited • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of BH3120, as a single agent and in combination with pembrolizumab, to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced or metastatic solid tumors. Dose-Escalation part i…
Phase: PHASE1 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Plasma zaps HPV: new hope for cervical infections?
Disease control Recruiting nowThis is a prospective, single-center, observational proof-of-principle clinical trial at the Department of Women's Health of the University Hospital Tübingen.
Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug aims to shield kidneys from dye damage during heart surgery
Disease control OngoingThis phase 2 study is to assess the safety and efficacy of APX-115 active doses in Contrast Induced Acute Kidney Disease compared to placebo following multiple oral dosing in patients with undergoing percutaneous coronary intervention. It is anticipated that approximately 230 pat…
Phase: PHASE2 • Sponsor: Aptabio Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Sleep apnea device may ease severe asthma symptoms
Disease control Recruiting nowThe aim of the study is to evaluate the impact of CPAP treatment on asthma control in patients with severe uncontrolled asthma and obstructive sleep apnea (OSA)
Phase: NA • Sponsor: Hospital Clinic of Barcelona • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New study aims to help cancer patients and families avoid crises with early coaching calls
Symptom relief Recruiting nowThe current interdisciplinary specialist palliative care model focuses on supporting patients with advanced cancer who have complex problems in the last weeks of life. Consequently, palliative care is often provided late and in response to uncontrolled symptoms during crises. Pal…
Phase: NA • Sponsor: National Cancer Centre, Singapore • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
New pill could ease severe depression
Symptom relief CompletedThe purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
Phase: PHASE2 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
New pill takes on Hard-to-Treat prostate cancer
Disease control Recruiting nowThe overall objective of this Phase 1 study is to evaluate the safety, PK,and anti-tumor activity of daily oral dosing with HP518,selecting the RP2D of HP518 based on assessments of patients with progressive mCRPC in dose-escalation phase
Phase: PHASE1, PHASE2 • Sponsor: Hinova Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could an iPhone app help beat eating disorders?
Symptom relief OngoingThis project aims to assess the efficacy of the Juniver program on symptoms of eating disorders via a randomised controlled trial. The Juniver program is a self-help intervention for eating disorders delivered digitally, through an iPhone app. It features three components: an evi…
Phase: NA • Sponsor: King's College London • Aim: Symptom relief
Last updated Jun 26, 2026 15:00 UTC
-
New glasses film may help Kids' eyesight stop getting worse
Disease control OngoingThere are two parts to this trial. First, to compare the rate of myopia progression of spectacle films using Spatio Temporal Optic Phase (S.T.O.P.®) technology that provide a dynamic optical cue against single vision spectacle lenses. Second, to compare the rate of myopia progres…
Phase: NA • Sponsor: nthalmic Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise for rare High-Cholesterol disease
Disease control CompletedThis is a single-arm, open-label study to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with homozygous familial hypercholesterolemia (HoFH).
Phase: PHASE2 • Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 13:33 UTC
-
Can two old drugs together save young livers?
Disease control CompletedChildren with decompensated cirrhosis are more prone to develop various complications. The pathogenesis of cirrhotic complications (ascites, hyponatremia, acute kidney injury) includes release of vasodilatory molecules like nitric oxide, damage associated molecular pathogens (DAM…
Phase: NA • Sponsor: Institute of Liver and Biliary Sciences, India • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can a failed ALS drug help PSP patients? new trial results are in
Disease control CompletedA35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label extension phase.
Phase: PHASE2, PHASE3 • Sponsor: Amylyx Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New hope for Hard-to-Treat myeloma: drug combo targets resistant cancer
Disease control OngoingThis phase Ib trial tests the safety, side effects, and best dose of CC-92480 in combination with elotuzumab and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment or has not r…
Phase: PHASE1 • Sponsor: Abdullah Khan • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Double cord blood transplant: a new hope for adults with blood cancer?
Disease control Recruiting nowThe efficacy and safety of non-myeloablative and myeloablative preconditioning followed by dual-unit umbilical cord blood transplantation from unrelated donors in adult patients with malignant hematologic diseases eligible for allogeneic hematopoietic stem cell transplantation ar…
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New heart failure pill shows promise in early trial
Disease control CompletedThis study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.
Phase: PHASE2 • Sponsor: Akros Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for rare disease: can NS-229 help patients reduce steroids?
Disease control OngoingThis study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.
Phase: PHASE2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Breathing easier, lowering pressure: HEPA filters tested in NYC housing
Disease control Recruiting nowFine particulate matter \<2.5 µm (PM2.5) air pollution is the fifth leading risk factor for global mortality, with the largest portion of deaths due to cardiovascular disease (CVD). While several mechanisms are responsible, PM2.5-induced elevations in blood pressure (BP) may be r…
Phase: NA • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New antibody therapy targets rare blood cancers in first human trial
Disease control Recruiting nowThe purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968 in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s) in part 2 (Cohort Expansion). For U.S. …
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC